Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase II drugs for Castration-Resistant Prostate Cancer (CRPC) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abiraterone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abiraterone (DST-2970, KABE) is under development for the treatment of castrate sensitive or castrate resistant adenocarcinoma of the prostate. It is administered through oral route formulated as tablet. The therapeutic candidate acts by targeting 17 alpha-hydroxylase/C17,20-lyase (CYP17). The drug candidate is developed based on Kinetisol technology.
Austhera BioSciences overview
Austhera BioSciences is a pharmaceutical development company that develops transformative drug candidates and novel chemical entities for the treatment of cancer and rare diseases. Austhera BioSciences is headquartered in Georgetown, Texas, the US.
For a complete picture of Abiraterone’s drug-specific PTSR and LoA scores, buy the report here.